MIP 1095 I-131

Drug Profile

MIP 1095 I-131

Alternative Names: 1095; 123I-MIP-1095; [131I] MIP-1095; I131-MIP-1095; MIP-1095; MIP-1095 I123; MIP-1095 I131

Latest Information Update: 20 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Molecular Insight Pharmaceuticals
  • Developer Progenics Pharmaceuticals
  • Class Imaging agents; Radiopharmaceutical diagnostics; Radiopharmaceuticals; Small molecules
  • Mechanism of Action Glutamate carboxypeptidase II inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 14 Feb 2017 Pharmacodynamics data from a preclinical study in Prostate cancer released by Progenics Pharmaceuticals
  • 19 Jan 2017 Phase-I clinical trials in Prostate cancer (Metastatic disease) in USA (unspecified route)
  • 08 Jun 2010 Preclinical trials in Prostate cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top